These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 27064343)

  • 1. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.
    Walter RF; Mairinger FD; Werner R; Vollbrecht C; Hager T; Schmid KW; Wohlschlaeger J; Christoph DC
    Oncotarget; 2016 Apr; 7(15):20166-79. PubMed ID: 27064343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.
    Walter RF; Werner R; Ting S; Vollbrecht C; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J; Mairinger FD
    Oncotarget; 2015 Sep; 6(28):24690-8. PubMed ID: 26008974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014).
    Saber M; Ismail Y; Alieldin N; Loay I; El Zawahry M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):151-158. PubMed ID: 30470605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
    Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
    Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
    Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
    J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
    Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
    Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
    Schnabel PA; Junker K
    Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
    Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
    Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
    Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
    Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses.
    Yeh YC; Chou TY
    J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis on the characteristics and prognosis of pulmonary neuroendocrine tumors.
    Wu BS; Hu Y; Sun J; Wang JL; Wang P; Dong WW; Tao HT; Gao WJ
    Asian Pac J Cancer Prev; 2014; 15(5):2205-10. PubMed ID: 24716958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
    Walch AK; Zitzelsberger HF; Aubele MM; Mattis AE; Bauchinger M; Candidus S; Präuer HW; Werner M; Höfler H
    Am J Pathol; 1998 Oct; 153(4):1089-98. PubMed ID: 9777940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine.
    Travis WD
    Thorac Surg Clin; 2014 Aug; 24(3):257-66. PubMed ID: 25065926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
    Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
    Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
    Kinoshita T; Yoshida J; Ishii G; Aokage K; Hishida T; Nagai K
    Clin Lung Cancer; 2013 Sep; 14(5):535-40. PubMed ID: 23792008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
    Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y
    Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression in neuroendocrine tumors of the lung.
    Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y
    Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
    Cai L; Liu H; Huang F; Fujimoto J; Girard L; Chen J; Li Y; Zhang YA; Deb D; Stastny V; Pozo K; Kuo CS; Jia G; Yang C; Zou W; Alomar A; Huffman K; Papari-Zareei M; Yang L; Drapkin B; Akbay EA; Shames DS; Wistuba II; Wang T; Johnson JE; Xiao G; DeBerardinis RJ; Minna JD; Xie Y; Gazdar AF
    Commun Biol; 2021 Mar; 4(1):314. PubMed ID: 33750914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.